DAWN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Day One Biopharmaceuticals Inc (DAWN) is not a good buy for a beginner, long-term investor at this time. The stock is being acquired by Servier at a fixed price of $21.50 per share, which limits any upside potential. The acquisition has already been finalized, and the stock price is trading at the acquisition price, leaving no room for growth or significant returns.
The technical indicators show mixed signals. The MACD is negative and contracting, RSI is neutral at 79.464, and moving averages are bullish. However, the stock is trading at the acquisition price of $21.50, which caps any meaningful price movement.
The acquisition by Servier enhances their oncology portfolio and positions them as a leader in low-grade glioma treatments. Day One's FDA-approved OJEMDATM (tovorafenib) adds value to Servier's product line.
The acquisition at $21.50 per share fixes the stock's value, eliminating potential upside. Analysts have downgraded the stock to Neutral, reflecting the limited growth opportunity.
In Q4 2025, revenue increased by 83.92% YoY to $53.7M, but net income dropped by -67.62% YoY to -$21.28M. EPS also declined by -67.19% YoY to -$0.21, and gross margin slightly decreased to 88.68%.
All analysts have downgraded the stock to Neutral with a price target of $21.50, citing the acquisition by Servier. This reflects the consensus that the stock's value is now capped at the acquisition price.
